SFDA To Establish Early Warning System For Drugs
This article was originally published in PharmAsia News
Executive Summary
China State FDA will establish an early warning system as well as adopt coordinated steps to prevent or minimize harm to the public from adverse drug effects. Since setting up a notification procedure in 2001, the health care community and patients have been informed of 49 drugs with potential issues. SFDA will, according to the degree of risk, undertake five measures to supervise drugs with reported adverse reactions: (1) order drug producers to modify the product package inserts; (2) suspend the affected drugs' sale and use; (3) get drug manufacturers to improve production techniques; (4) convert OTC to prescription drugs; and (5) demand the drugs to be withdrawn from the market. (Click here for more - Chinese Language)
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.